The stock is a binary catalyst play on BLA submission and FDA feedback. Key near-term catalysts: topline OL data (any day now), Type B FDA meeting outcome, and rolling BLA initiation in June. The $200.4M cash runway removes near-term financing risk. Watch for any FDA pushback on the surrogate endpoint or safety database adequacy — that would be a major negative. The 7 anaphylaxis cases in the OL study (out of 39) remain a safety overhang for the BLA review.
Price Chart
Executive Summary
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025, with no revenue. The filing highlights continued FDA alignment for a rolling BLA submission seeking accelerated approval for nomlabofusp in Friedreich's ataxia, with nonclinical/clinical modules planned for June 2026 and CMC module in 2H 2026. Cash position strengthened to $200.4M (post-February $107.6M net offering), extending runway into Q2 2027. The stock will move on upcoming binary catalysts: topline open-label data (Q2 2026), Type B FDA meeting, and BLA submission progress.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $29.6M ($0.31/share) vs $29.3M ($0.46/share) in Q1 2025 — loss per share improved on higher share count
- Cash, cash equivalents and marketable securities of $200.4M as of March 31, 2026, with projected runway into Q2 2027
- Planning rolling BLA submission seeking accelerated approval: nonclinical/clinical modules June 2026, CMC module 2H 2026
- Type B meeting with FDA scheduled later in Q2 2026 to align on BLA data package readiness
- Topline open-label study data expected Q2 2026; first patient dosing in global Phase 3 confirmatory study expected mid-2026
- Breakthrough Therapy Designation granted February 2026; FDA aligned on FXN as surrogate endpoint
- February 2026 public offering raised $107.6M net proceeds; 103.9M shares outstanding as of March 31, 2026 (up from 83.1M at Dec 31, 2025)
- No revenue; pre-revenue clinical-stage biotech
Financial Impact
No revenue; net loss $29.6M in Q1 2026; cash burn rate ~$10M/month; $200.4M cash runway into Q2 2027
Risk Factors
- FDA may not accept FXN as a surrogate endpoint for accelerated approval — BLA submission could be delayed or require additional data
- 7 of 39 OL study participants experienced anaphylaxis — safety database adequacy will be reviewed at BLA submission
- Rolling BLA strategy is pending FDA feedback from Type B meeting — could change if FDA disagrees
- No approved product; pre-revenue with history of net losses; dilution risk from additional capital raises
- Competing therapies (Skyclarys/omaveloxolone) already approved for FA, though they do not address frataxin deficiency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222746 |
| Document: lrmr-ex99_2.htm | 0001193125-26-222746 |
| Document: lrmr-20260514.htm | 0001193125-26-222746 |
| Document: 0001193125-26-222746-index-headers.html | 0001193125-26-222746 |
| Document: 0001193125-26-222746-index.html | 0001193125-26-222746 |
| Document: 0001193125-26-222746.txt | 0001193125-26-222746 |
| 8-K Data (Synthetic) | 0001193125-26-222746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 14, 2026 20w ago | 8-K | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.97 (−23.65%) |
May 14, 2026 20w ago | Press Release | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.97 (−23.65%) |
Mar 19, 2026 28w ago | Press Release | $4.47 $3.59 | ▼ −19.69% | ▼ −34.03% | $2.97 (−33.56%) |
Feb 27, 2026 31w ago | 8-K | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access